Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Tuberc Lung Dis ; 15(7): 949-54, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21682970

ABSTRACT

BACKGROUND: Delamanid (OPC-67683) is a novel mycolic acid biosynthesis inhibitor active against Mycobacterium tuberculosis at a low minimum inhibitory concentration. METHODS: Forty-eight patients with smear-positive tuberculosis (63% male; 54.7 ± 9.9 kg; 30.7 ± 10.8 years) were randomly assigned to receive delamanid 100, 200, 300 or 400 mg daily for 14 days. Colony forming units (cfu) of M. tuberculosis were counted on agar plates from overnight sputum collections to calculate early bactericidal activity (EBA), defined as fall in log(10) cfu/ml sputum/day. RESULTS: The EBA of delamanid was monophasic and not significantly different between dosages; however, more patients receiving 200 mg (70%) and 300 mg (80%) experienced a response of ≥0.9 log(10) cfu/ml sputum decline over 14 days than those receiving 100 mg (45%) and 400 mg (27%). The average EBA of all dosages combined (0.040 ± 0.056 log(10) cfu/ml sputum/day) was significant from day 2 onward. Delamanid exposure was less than dosage-proportional, reaching a plateau at 300 mg, likely due to dose-limited absorption. Moderate but significant correlation was found between C(max) and EBA, indicating exposure dependence. Delamanid was well tolerated without significant toxicity. CONCLUSIONS: Delamanid at all dosages was safe, well tolerated and demonstrated significant exposure-dependent EBA over 14 days, supporting further investigation of its pharmacokinetics and anti-tuberculosis activity.


Subject(s)
Antitubercular Agents/therapeutic use , Mycobacterium tuberculosis/drug effects , Nitroimidazoles/therapeutic use , Oxazoles/therapeutic use , Tuberculosis, Pulmonary/drug therapy , Adolescent , Adult , Antitubercular Agents/administration & dosage , Antitubercular Agents/adverse effects , Colony Count, Microbial , Dose-Response Relationship, Drug , Female , Humans , Male , Microbial Sensitivity Tests , Middle Aged , Mycobacterium tuberculosis/isolation & purification , Nitroimidazoles/administration & dosage , Nitroimidazoles/adverse effects , Oxazoles/administration & dosage , Oxazoles/adverse effects , Sputum/microbiology , Treatment Outcome , Tuberculosis, Pulmonary/microbiology , Young Adult
2.
Clin Pharmacol Ther ; 88(3): 375-82, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20686477

ABSTRACT

A model-based approach was used to integrate data from a phase II study in order to provide a quantitative rationale for selecting the apixaban dosage regimen for a phase III trial. The exposure-response models demonstrated that an increase in daily steady-state area under the plasma concentration-vs.-time curve (AUC(ss)) of 1 microg x h/ml would increase the odds ratio for major bleeding by 0.118 and decrease the odds ratio for venous thromboembolism (VTE) by 0.0499. The therapeutic utility index (TUI) was used to integrate the efficacy and safety predictions to quantify apixaban's efficacy/safety balance as a function of AUC(ss). Of the apixaban dosage regimens tested in phase II, the 2.5 mg twice-daily (b.i.d.) dosage regimen had the highest TUI (86.2%). This was also higher than the TUI for either 30 mg b.i.d. enoxaparin (82.5%) or for warfarin (71.8%). Subjects with moderate renal impairment are expected to have a 43% increase in apixaban exposure; however, apixaban's TUI suggests that dose adjustment is not needed in these subjects with renal impairment.


Subject(s)
Fibrinolytic Agents/pharmacology , Hemorrhage/chemically induced , Models, Biological , Pyrazoles/pharmacology , Pyridones/pharmacology , Venous Thromboembolism/prevention & control , Aged , Area Under Curve , Clinical Trials, Phase II as Topic , Clinical Trials, Phase III as Topic/methods , Computer Simulation , Dose-Response Relationship, Drug , Enoxaparin/administration & dosage , Enoxaparin/pharmacology , Female , Fibrinolytic Agents/administration & dosage , Fibrinolytic Agents/adverse effects , Humans , Kidney Diseases/complications , Male , Pyrazoles/administration & dosage , Pyrazoles/adverse effects , Pyridones/administration & dosage , Pyridones/adverse effects , Warfarin/administration & dosage , Warfarin/pharmacology
3.
Invest New Drugs ; 14(2): 147-51, 1996.
Article in English | MEDLINE | ID: mdl-8913835

ABSTRACT

The binding of docetaxel to human plasma proteins was studied by ultrafiltration at 37 degrees C and pH 7.4. Docetaxel was extensively (> 98%) plasma protein bound. At clinically relevant concentrations (1-5 micrograms/ml), the plasma binding was concentration-independent. Lipoproteins, alpha1-acid glycoprotein and albumin were the main carriers of docetaxel in plasma, and owing to the high interindividual variability of alpha1-acid glycoprotein plasma concentration, particularly in cancer, it was concluded that alpha1-acid glycoprotein should be the main determinant of docetaxel plasma binding variability. Drugs potentially coadministered with docetaxel (cisplatin, dexamethasone, doxorubicin, etoposide, vinblastine) did not modify the plasma binding of docetaxel. In blood, docetaxel was found to be mainly located in the plasma compartment (less than 15% associated to erythrocytes).


Subject(s)
Antineoplastic Agents, Phytogenic/blood , Blood Proteins/metabolism , Orosomucoid/metabolism , Paclitaxel/analogs & derivatives , Taxoids , Cells, Cultured , Docetaxel , Erythrocytes/metabolism , Humans , Kinetics , Paclitaxel/blood , Protein Binding
SELECTION OF CITATIONS
SEARCH DETAIL
...